Saint-Romuald, Canada Clinical Trials

A listing of Saint-Romuald, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 128 clinical trials
Trial of Andexanet in ICH Patients Receiving an Oral FXa Inhibitor

Randomized, controlled clinical trial evaluating the efficacy and safety of andexanet versus usual standard of care in patients with intracranial hemorrhage anticoagulated with a direct oral anticoagulant

CHU de Quebec-Universite Laval, H pital de l'Enfant J sus
 (5.5 away) Contact site
  • 19 views
  • 17 Jul, 2021
  • +180 other locations
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

Sometimes, cancer patients receive an initial treatment, followed by additional treatment to lower the chance of cancer coming back. The standard or usual treatment for this type of disease is initially having radiation therapy at the same time as chemotherapy (with a drug called cisplatin), with no additional therapy afterwards

carcinoma
x-rays
oropharyngeal carcinoma
neutrophil count
pet/ct scan
CHUQ-Pavillon Hotel-Dieu de Quebec
 (4.2 away) Contact site
  • 56 views
  • 21 Jul, 2021
  • +29 other locations
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).

CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 0204)
 (4.2 away) Contact site
  • 135 views
  • 11 Jul, 2021
  • +146 other locations
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer

Novartis Investigative Site
 (2.9 away) Contact site
  • 211 views
  • 17 Jul, 2021
  • +362 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

This study will evaluate the efficacy and safety of pembrolizumab (MK-3475) with lenvatinib (E7080/MK-7902) vs. docetaxel in participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti-PD-1/PD-L1 monoclonal antibody (mAb). The primary hypotheses of this study are that …

pembrolizumab
measurable disease
monoclonal antibodies
cancer
mk-3475
CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 1514)
 (4.2 away) Contact site
  • 122 views
  • 23 Jul, 2021
  • +149 other locations
A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer

In this study researchers want to gather relevant information regarding the safety of BAY2416964 and how well the drug works in participants with a type of solid tumors that cannot be cured by currently available drugs. Researchers want to find the highest dose of BAY2416964 that participants could take without …

Centre Hospitalier Universitaire de Quebec (CHUQ)
 (4.1 away) Contact site
  • 2 views
  • 16 Jul, 2021
  • +19 other locations
A Study of the Efficacy and Safety of MEDI7352 in Subjects With Painful Osteoarthritis of the Knee

This is a Phase 2b randomised, double-blind, placebo-controlled, dose-response study in subjects with painful osteoarthritis (OA) of the knee. The study will assess the safety and efficacy of multiple doses of MEDI7352 compared to placebo, as well as the pharmacokinetics, pharmacodynamics and immunogenicity of MEDI7352 in subjects with moderate to …

Research Site
 (2.9 away) Contact site
  • 0 views
  • 17 Jul, 2021
  • +58 other locations
Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

The purpose of this study is to evaluate the efficacy and safety of brolucizumab compared to panretinal photocoagulation laser (PRP) in patients with proliferative diabetic retinopathy (PDR). This evaluation will provide information that brolucizumab is non-inferior to PRP with respect to the change in best corrected visual acuity at Week …

Novartis Investigative Site
 (2.2 away) Contact site
  • 0 views
  • 21 Jul, 2021
  • +69 other locations
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer.

This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and expansion study including an intra-participant ramp-up. AZD4573 will be administered intravenously, in novel combinations with anti-cancer agents, to participants with relapsed/refractory haematological malignancies.

Research Site
 (2.9 away) Contact site
  • 0 views
  • 20 Jul, 2021
  • +28 other locations
A Study of AKCEA-APOCIII-LRx Administered to Patients With Familial Chylomicronemia Syndrome (FCS)

The purpose of the study is to evaluate the efficacy of AKCEA-APOCIII-LRx as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.

IONIS Investigative Site
 (2.2 away) Contact site
  • 0 views
  • 21 Jul, 2021
  • +25 other locations